PT Sarana Meditama Metropolitan Tbk (IDX:SAME)
Indonesia · Delayed Price · Currency is IDR 326.00
+6.00 (1.88%)
Aug 8, 2025, 3:46 PM WIB
Ligand Pharmaceuticals Cash Flow Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 31,166 | 11,849 | 12,252 | 4,347 | 144,169 | -187,643 | Upgrade |
Depreciation & Amortization | 209,302 | 212,293 | 220,504 | 203,239 | 149,778 | 92,980 | Upgrade |
Other Operating Activities | -41,184 | 39,281 | -96,609 | -46,167 | -40,207 | 72,996 | Upgrade |
Operating Cash Flow | 199,284 | 263,422 | 136,148 | 161,419 | 253,740 | -21,667 | Upgrade |
Operating Cash Flow Growth | -24.64% | 93.48% | -15.66% | -36.38% | - | - | Upgrade |
Capital Expenditures | -296,902 | -263,913 | -456,921 | -166,203 | -139,041 | -87,785 | Upgrade |
Sale of Property, Plant & Equipment | 382.26 | 252.78 | 961.68 | 2,698 | 4,837 | 884.93 | Upgrade |
Cash Acquisitions | - | - | - | -506,289 | -2,069,966 | - | Upgrade |
Sale (Purchase) of Intangibles | -9,153 | -23,498 | -58,597 | -74,514 | - | - | Upgrade |
Investment in Securities | 34,000 | 17,000 | -9,500 | -307,819 | -99,933 | - | Upgrade |
Other Investing Activities | 18,689 | 20,021 | 15,400 | - | - | - | Upgrade |
Investing Cash Flow | -252,985 | -250,137 | -508,657 | -1,052,128 | -2,304,103 | -86,900 | Upgrade |
Short-Term Debt Issued | - | 40,000 | 100,000 | - | - | - | Upgrade |
Long-Term Debt Issued | - | 987,269 | 216,000 | 784,000 | - | 29,100 | Upgrade |
Total Debt Issued | 1,086,155 | 1,027,269 | 316,000 | 784,000 | - | 29,100 | Upgrade |
Short-Term Debt Repaid | - | - | - | -9,058 | - | - | Upgrade |
Long-Term Debt Repaid | - | -1,020,017 | -99,349 | -81,048 | -1,192,681 | -37,659 | Upgrade |
Total Debt Repaid | -1,049,601 | -1,020,017 | -99,349 | -90,106 | -1,192,681 | -37,659 | Upgrade |
Net Debt Issued (Repaid) | 36,554 | 7,252 | 216,651 | 693,894 | -1,192,681 | -8,559 | Upgrade |
Issuance of Common Stock | - | - | - | - | 3,692,925 | - | Upgrade |
Other Financing Activities | -2,062 | -2,062 | -17,994 | -16,119 | 14,829 | 91,610 | Upgrade |
Financing Cash Flow | 34,492 | 5,190 | 198,657 | 677,775 | 2,515,072 | 83,051 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | -0 | Upgrade |
Net Cash Flow | -19,209 | 18,475 | -173,852 | -212,933 | 464,709 | -25,516 | Upgrade |
Free Cash Flow | -97,618 | -490.41 | -320,773 | -4,784 | 114,699 | -109,452 | Upgrade |
Free Cash Flow Margin | -5.63% | -0.03% | -20.94% | -0.34% | 9.02% | -13.40% | Upgrade |
Free Cash Flow Per Share | -5.69 | -0.03 | -18.72 | -0.28 | 8.47 | -16.41 | Upgrade |
Cash Interest Paid | 77,130 | 81,988 | 69,970 | 42,122 | 39,479 | 72,989 | Upgrade |
Cash Income Tax Paid | 18,808 | 22,031 | 24,046 | 32,010 | 31,635 | 58.06 | Upgrade |
Levered Free Cash Flow | -141,981 | -50,228 | -395,052 | -91,065 | 76,497 | -16,035 | Upgrade |
Unlevered Free Cash Flow | -95,883 | -752.28 | -351,441 | -65,823 | 102,181 | 55,615 | Upgrade |
Change in Net Working Capital | 68,365 | -10,483 | 86,056 | 49,706 | 31,783 | -59,182 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.